secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2025-09-02T23:59:59+00:00
Accession:  0001062993-25-015149
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus Pharma completes Antev acquisition for ~$3M cash + 1.6M shares; up to $65M contingent
--------------------------------------------------------------------------------

- Acquired 98.6% of Antev for ~$3.0M cash and 1,603,164 MDCX shares; up to $65M in contingent milestones tied to FDA Phase 2 and NDA approvals.
- Antev develops Teverelix, a GnRH antagonist for acute urinary retention and high-CV-risk prostate cancer; targets ~$6B market.
- Patrick J. Mahaffy, former Antev chairman and ex-CEO of Clovis Oncology, appointed to board; receives 25,000 stock options at $1.94 vesting quarterly over 12 months.
- Consideration shares subject to staggered 210-day lock-up (15% released every 30 days from effective registration; final 10% at 210 days).
- Sold 250,000 common shares to Yorkville via SEPA for ~$490,535 net proceeds; proceeds to prepay outstanding debentures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325015149/0001062993-25-015149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325015149/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-25-015149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer